Bio-Rad Laboratories, Inc.

NYSE:BIO Lagerbericht

Marktkapitalisierung: US$7.5b

Bio-Rad Laboratories Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Bio-Rad Laboratories wird ein jährliches Gewinn- und Umsatzwachstum von 3.6% bzw. 1.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 3.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 2.9% betragen.

Wichtige Informationen

3.6%

Wachstumsrate der Gewinne

3.64%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum17.5%
Wachstumsrate der Einnahmen1.7%
Zukünftige Eigenkapitalrendite2.93%
Analystenabdeckung

Low

Zuletzt aktualisiert19 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Analyseartikel • Aug 03

Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results

Investors in Bio-Rad Laboratories, Inc. ( NYSE:BIO ) had a good week, as its shares rose 7.7% to close at US$285...

Recent updates

Narrativ-Update • May 15

BIO: Share Repurchases Will Support Future Upside Despite Lower Margin Outlook

Analysts have trimmed their price target on Bio-Rad Laboratories from $321.25 to $293.00, reflecting updated views on growth, margins, discount rate, and future P/E assumptions. What's in the News From January 1, 2026 to March 31, 2026, Bio-Rad Laboratories repurchased 176,257 shares for US$47.42 million, equal to 0.65% of its shares.
Narrativ-Update • Apr 29

BIO: Completed Buybacks And Intangible Impairment Will Support Future Upside

Analysts maintained their $320.00 price target for Bio-Rad Laboratories, making only minor adjustments to assumptions for discount rate, revenue, profit margin, and future P/E ratio to support this unchanged outlook. What's in the News Reported impairment charges of purchased intangibles and related items of $172.8 million for the fourth quarter ended December 31, 2025 (Key Developments).
Narrativ-Update • Apr 15

BIO: Buybacks And Intangible Impairment Will Shape Balanced Forward Expectations

Analysts have reset their price target on Bio-Rad Laboratories from $375 to $320, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for a total of US$715.43 million under the buyback program announced on July 20, 2023 (Key Developments).
Narrativ-Update • Mar 31

BIO: Share Repurchase And Higher Margin Outlook Will Support Future Upside

Analysts have reduced their price target on Bio-Rad Laboratories from $348.00 to $321.25, reflecting updated assumptions for revenue growth, profit margins, discount rate and future P/E that result in a slightly more conservative valuation framework. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for a total of US$715.43m under the buyback that was announced on July 20, 2023 (Key Developments).
Narrativ-Update • Mar 17

BIO: Share Repurchases And Intangible Impairment Will Shape Future Upside

Analysts have maintained their $375.00 price target for Bio-Rad Laboratories, citing only minor adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E to reflect updated model inputs rather than a change in their overall view. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for a total of US$715.43m under the buyback announced on July 20, 2023 (Key Developments).
Narrativ-Update • Mar 03

BIO: Share Repurchases And Margin Outlook Will Support Future Upside

Analysts have maintained their price target for Bio-Rad Laboratories at $375, citing updated assumptions that include slightly higher revenue, improved profit margins, and a lower future P/E multiple, which together support the unchanged assessment of fair value. What's in the News From October 1, 2025 to December 31, 2025, Bio-Rad Laboratories reported no additional share repurchases, with 0 shares bought for $0, under its existing buyback program (Key Developments).
Narrativ-Update • Feb 17

BIO: Share Repurchases Will Support Future Upside Despite Impairment Charges

Analysts are keeping their price target for Bio-Rad Laboratories steady at $375, with updated assumptions that include a slightly higher discount rate, a higher revenue growth outlook, a lower profit margin, and a higher future P/E multiple to reflect their latest view of the risk and return profile. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of the company, for a total of US$715.43 million under the buyback announced on July 20, 2023 (Key Developments).
Narrativ-Update • Feb 03

BIO: Fair Outlook Will Balance Richer Margins Against Higher Required Returns

Analysts have lifted their price target on Bio-Rad Laboratories from US$265 to US$325, reflecting updated views on slightly different growth assumptions, a higher projected profit margin, and an adjusted future P/E multiple. Valuation Changes Fair Value: updated from US$265 to US$325, indicating a higher implied valuation level.
Seeking Alpha • Jan 22

Bio-Rad Laboratories Still Hampered By Underwhelming Core Growth

Summary Bio-Rad remains undervalued, but persistent end-market headwinds and limited core growth drivers temper my conviction. BIO's valuation is heavily influenced by its substantial Sartorius stake, and the latter's bioprocessing business is looking better of late. Management's guidance has been volatile, with 2025 core revenue growth targets fluctuating from 2.5% to near zero, then modestly rebounding. ddPCR is a bright spot, but broader revenue growth remains constrained; I see fair value at $338–$390, with rerating contingent on sustained growth. Read the full article on Seeking Alpha
Narrativ-Update • Jan 20

BIO: Share Buybacks And Oncology Assay Partnership Will Drive Future Upside

Analysts have kept their price target for Bio-Rad Laboratories broadly steady at about US$375.00, reflecting only slight adjustments to modeled discount rate, revenue growth, profit margin, and future P/E assumptions in their updated views. What's in the News From July 1, 2025 to September 30, 2025, Bio-Rad repurchased 212,578 shares, about 0.79% of its shares, for US$52.83 million under its existing buyback program.
Analyseartikel • Jan 06

Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Key Insights Bio-Rad Laboratories' estimated fair value is US$394 based on 2 Stage Free Cash Flow to Equity Current...
Narrativ-Update • Jan 06

BIO: Share Buybacks And Oncology Partnership Will Support Future Upside

Analysts have lowered their price target on Bio-Rad Laboratories from US$437 to US$375, based on updated assumptions that combine more moderate revenue growth expectations with a slightly higher discount rate and a lower future P/E, partially offset by a higher projected profit margin. What's in the News Completed share repurchase of 2,614,132 shares, or 9.26% of the company, for a total of US$715.43m under the buyback announced on July 20, 2023 (Key Developments).
Narrativ-Update • Dec 14

BIO: Share Repurchase Will Drive Attractive Shareholder Returns Ahead

Narrative Update on Bio-Rad Laboratories Analysts have reaffirmed their conviction in Bio-Rad Laboratories, with the price target effectively unchanged at approximately 348 dollars. Modest tweaks to the discount rate, long-term revenue growth, profit margin, and future valuation assumptions largely offset one another in updated models.
Narrativ-Update • Nov 28

BIO: Share Repurchase and Expanded Partnership Will Shape Performance in Coming Quarters

Analysts have maintained their price target for Bio-Rad Laboratories at $348.00, noting only minor adjustments to revenue growth and profit margin expectations this quarter. What's in the News Bio-Rad Laboratories completed the repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for $715.43 million under a buyback program announced in July 2023.
Narrativ-Update • Nov 14

BIO: Share Repurchase and Expanded Partnerships Will Influence Future Performance

Analysts have raised their price target for Bio-Rad Laboratories from $324 to $348. They cite updated financial assumptions as well as small shifts in projected growth rates and profitability.
Narrativ-Update • Oct 30

BIO: Expanded Diagnostics Partnership Will Drive Margin Improvements Amid Mixed Revenue Outlook

Analysts have raised their price target for Bio-Rad Laboratories from $310 to $324, reflecting updated profit margin estimates. These changes more than offset slightly lower revenue growth expectations.
Narrativ-Update • Sep 28

Molecular Diagnostics Expansion Will Unlock Potential While Cost Challenges Persist

The decline in Bio-Rad Laboratories’ consensus price target to $310.00 primarily reflects lower future P/E and revenue growth expectations. What's in the News Completed buyback of 2,401,554 shares (8.47% of outstanding) for $662.6 million under program announced July 2023.
Analyseartikel • Aug 03

Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results

Investors in Bio-Rad Laboratories, Inc. ( NYSE:BIO ) had a good week, as its shares rose 7.7% to close at US$285...
Analyseartikel • Jul 14

We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
User avatar
Neues Narrativ • May 13

Acquisition And Droplet Digital PCR Will Advance Oncology Diagnostics

Bio-Rad's efforts in digital PCR technology and strategic acquisitions aim to expand applications and bolster revenue through oncology diagnostics and rare mutation detection.
Seeking Alpha • Jan 29

Bio-Rad: Uncertainties And Conservatism Continue To Hold Stock Back From Its Full Potential

Summary Bio-Rad has been challenged by tough end-market conditions in life sciences tools, but the outlook for 2025 is better. The company's cautious approach has led to lackluster sales growth and margin leverage over the long term, and there are only a handful of meaningful revenue drivers with above-average potential. I believe BIO management has long been too conservative and unfocused with its R&D spending, but recent commentary suggests that growth potential and ROI will play a bigger role going forward. Bio-Rad's stake in Sartorius remains a significant store of value, but management's long-term plans remain unclear. While undervalued and having potential for longer-term growth upside, I remain cautious due to management and strategic concerns, as well as a large reliance on Sartorius to drive overall value. Read the full article on Seeking Alpha
Seeking Alpha • Nov 25

Why Bio-Rad Laboratories Is Overvalued: A Fundamental And DCF Analysis

Summary Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net sales are expected to decline in 2024. Valuing Bio-Rad using a discounted cash flow model indicates that the BIO stock is overvalued by 20.10%. Read the full article on Seeking Alpha
Seeking Alpha • Sep 23

Bio-Rad Laboratories: Overvalued Given Current Growth Prospects

Summary Bio-Rad Laboratories is buying back a considerable amount of its own stock given the shares' current valuation and growth prospects. Profits and sales are expected to rebound in FY2025. A fuller look at Bio-Rad Laboratories is provided in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Jul 14

Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar

Summary Bio-Rad Laboratories, Inc. is a multinational manufacturer and distributor of life science research and clinical diagnostics products. The company's stock has been underperforming due to various pressures, including its position in Sartorius AG. Despite potential catalysts like product launches, the stock is considered overvalued with weak returns on capital and declining margins. Read the full article on Seeking Alpha
Seeking Alpha • Apr 14

Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker

Summary Bio-Rad is a "picks and shovels" company in the life sciences industry, but lacks standout growth, margins, or returns, and that has been largely true for more than two decades. Recent trends in the life sciences space have been challenging, driving, double-digit declines in Bio-Rad's Life Sciences segment, and neither biopharma nor academic/government budgets look great for 2024. Bio-Rad's holdings in Sartorius bring significant value to the company, but Sartorius shares have sold off considerably since the bioproduction bubble popped and investor enthusiasm has faded. There's an interesting some-of-the-parts story here, particularly if bioproduction growth resumes after a period of capacity digestion, but it's hard to love Bio-Rad on a standalone basis. Read the full article on Seeking Alpha
Seeking Alpha • Oct 25

Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance

Summary Bio-Rad Laboratories' investment returns are expected to be hindered by economic and technical factors. The company's large ownership in Sartorius AG has been a hindrance due to the latter's poor performance and high correlations between the pair. Bio-Rad's business returns are not attractive nor economically valuable, leading the market to push its equity value further to the downside. Read the full article on Seeking Alpha

Gewinn- und Umsatzwachstumsprognosen

NYSE:BIO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20282,6762283264673
12/31/20272,6362303154465
12/31/20262,5692253164615
3/31/20262,590169357510N/A
12/31/20252,583760375532N/A
9/30/20252,558-676337492N/A
6/30/20252,554319348534N/A
3/31/20252,541-2,164332515N/A
12/31/20242,567-1,844266455N/A
9/30/20242,580-779224412N/A
6/30/20242,563-1,326177346N/A
3/31/20242,605-322185347N/A
12/31/20232,671-637218375N/A
9/30/20232,720-159223374N/A
6/30/20232,769-428153287N/A
3/31/20232,779-191125242N/A
12/31/20222,802-3,62780194N/A
9/30/20222,805-6,021152286N/A
6/30/20222,871-1,930364505N/A
3/31/20222,896-91459606N/A
12/31/20212,9234,254536670N/A
9/30/20212,9806,659670783N/A
6/30/20212,8804,045590689N/A
3/31/20212,7014,098533626N/A
12/31/20202,5463,814480585N/A
9/30/20202,3803,521378450N/A
6/30/20202,2941,947323414N/A
3/31/20202,3291,579383478N/A
12/31/20192,3121,759N/A458N/A
9/30/20192,304377N/A403N/A
6/30/20192,289905N/A366N/A
3/31/20192,292574N/A288N/A
12/31/20182,289366N/A285N/A
9/30/20182,2941,277N/A250N/A
6/30/20182,2831,030N/A216N/A
3/31/20182,212767N/A201N/A
12/31/20172,160122N/A104N/A
9/30/20172,11017N/A130N/A
6/30/20172,08513N/A153N/A
3/31/20172,09726N/A168N/A
12/31/20162,06826N/A216N/A
9/30/20162,06798N/A157N/A
6/30/20162,02897N/A188N/A
3/31/20162,018108N/A149N/A
12/31/20152,019109N/A186N/A
9/30/20152,047103N/A190N/A
6/30/20152,10897N/A199N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BIODas prognostizierte Gewinnwachstum (3.6% pro Jahr) liegt über der Sparquote (3.5%).

Ertrag vs. Markt: BIODie Erträge des Unternehmens (3.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (16.8% pro Jahr).

Hohe Wachstumserträge: BIODie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: BIODie Einnahmen des Unternehmens (1.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.6% pro Jahr).

Hohe Wachstumseinnahmen: BIODie Einnahmen des Unternehmens (1.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BIODie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (2.9%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/20 08:40
Aktienkurs zum Tagesende2026/05/20 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Bio-Rad Laboratories, Inc. wird von 19 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Jon WoodBofA Global Research
Yuan ZhiB. Riley Securities, Inc.
Patrick DonnellyCitigroup Inc